Biocon Limited BIOCON

Biocon Biologics Limited, a wholly-owned subsidiary of Biocon Limited (BSE: 532523) (NSE: BIOCON), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the granting of a marketing authorisation to its Pertuzumab biosimilar as 420 mg concentrate solution for infusion, under the brand name Pebrilzo®, for the treatment of HER2–positive breast cancer across multiple disease stages.

Biocon’s updated analyst model now points to a fair value of ₹446.89, compared with the earlier estimate of ₹429.67, which translates to a roughly 4% uplift in the price target. Recent analyst commentary links this higher fair value to views on Biocon’s execution quality, earnings visibility, and how the current risk profile compares with that new target. As you read on, you will see how this revised price target fits into the evolving narrative around the stock and what it may mean for your...

Tariff threats from the US are colliding with India’s export surge, and that clash is putting a fresh spotlight on large-cap exporters with heavy US exposure. Some stocks could see pressure if trade friction bites. Others may benefit as supply chains and free trade deals are rewired. This article breaks down three such stocks from the screener and how this news could matter for your portfolio decisions. The three stocks covered below are just a sample from this theme, and the full screen...

Biocon’s updated valuation work now points to a fair value price target of ₹429.67, compared with the earlier figure of ₹416.53. Recent research on peers in life sciences and diagnostics highlights how analysts are weighing profitability plans and execution risk when assigning price targets, which helps explain why the shift for Biocon is measured rather than aggressive. As you read on, you will see how this latest move fits into the evolving Biocon narrative and what to watch next as new...

Biocon Ltd (BOM:532523) delivers robust Q1 FY27 with strong biosimilar and generics growth, offsetting Syngene's decline.

BENGALURU, India & BRIDGEWATER, N.J., August 03, 2026--Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron’s Eylea® 2 mg, Used to Treat Various Types of Ophthalmology Conditions

BENGALURU, India & BRIDGEWATER, N.J., July 09, 2026--Biocon Limited (BSE: 532523; NSE: BIOCON), an innovation‑led global biopharmaceutical company, today announced the publication of two important clinical studies supporting the effectiveness of Yesafili™ (aflibercept-jbvf). The clinical data from the Phase III INSIGHT program evaluating MYL‑1701P, its aflibercept biosimilar, was published in two peer-reviewed journals, contributing to the clinical evidence base supporting the development of afl

Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced that Siddharth Mittal has assumed the role of Managing Director and Chief Executive Officer of the Company, effective 1 July 2026.

Biocon Ltd (BOM:532523) reports robust revenue growth driven by biosimilars, strategic debt reduction, and key market expansions despite external challenges.

Biocon’s fair value estimate has been trimmed slightly from ₹420.74 to about ₹416.53, signalling a modest reset in how analysts are sizing up the stock today. That shift lines up with a broader, more cautious tone in recent research on life sciences companies, where execution risk, revenue trajectories and the market’s willingness to pay up after guidance disappointments are under close review. As you read on, you will see how these moving pieces shape the evolving Biocon narrative and what...

Consistently featured on the Forbes’ list of The World’s Most Powerful Women since 2011, Mazumdar-Shaw will also serve as the keynote speaker at the May 16 commencement ceremony.Claremont, CA, Feb. 25, 2026 (GLOBE NEWSWIRE) -- As part of Keck Graduate Institute’s 24th commencement ceremony in May 2026, Kiran Mazumdar-Shaw will receive an honorary Doctor of Philosophy in Applied Life Sciences degree in recognition of her illustrious career and passion for expanding access and affordability to hea

•New oncology assets to include proposed biosimilars for Trastuzumab/Hyaluronidase combination (Herceptin® SC/Herceptin HYLECTA™), Nivolumab (Opdivo®) and Pembrolizumab (Keytruda®) •Company to outline integration as a wholly owned subsidiary into Biocon Ltd., strengthening its global leadership in biosimilar insulins and GLP 1 peptide generics to cover the full spectrum of diabetes careBRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Biocon Biol